Inhibrx Biosciences, Inc.

INBX Healthcare Biotechnology

Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

89.83 0.67 −0.74%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−8.6×
Dividend yield
—
F-score
2/9
Altman Z
0.73
Beneish M
0.31
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(1,773.60%) (354.69%) (197.85%) (144.07%)

+8 more TTM periods

ROA
(75.44%) (61.03%) (85.60%) (77.54%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(118.27%) (87.95%) (136.29%) (119.53%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(8.42) (8.46) (8.38) (9.27)
Free Cash Flow
(131.89) (131.92) (129.82) (143.44)
Other line items

Show all line items

Columns are period end dates